IVD China last week: Sansure, Sinocare, Andon Health and Chromai, Rendu Biotech

Sansure Biotech 21% Revenue Growth, Overseas Business Up 60% in H1 2025

Sansure Biotech Inc. announced its 2025 half-year financial results, recording revenue of RMB 869 million, a 21.15% year-on-year increase. Net profit attributable to shareholders was CNY 163 million, up 3.84%, while non-recurring adjusted net profit reached RMB 136 million, representing 12.19% growth. By advancing integrated diagnostics and personalized innovation, the company has driven product upgrades and achieved multi-line development across respiratory diseases, maternal and child health, blood-borne infections, gene sequencing, immunodiagnostics, and pharmacogenomics, consolidating its industry-leading position.

The company further advanced its internationalization strategy of “platform integration and diagnostics integration.” In H1 2025, overseas revenue increased by more than 60% year-on-year, with products and solutions now serving over 160 countries and regions. Subsidiaries were established in Indonesia, France, and the UK, while in Sierra Leone the company initiated a national cervical cancer screening project, earning the “National Public Health Contribution Award.”

Sinocare Reports CNY 2.264 Billion Revenue, with Overseas Sales Exceeding 44% in H1 2025

Sinocare Inc. released its 2025 half-year report, reporting revenue of CNY 2.264 billion in the first half of the year, representing a 6.12% year-on-year increase. Net profit attributable to shareholders reached CNY 180 million. The performance was driven by the company’s global collaborative innovation strategy and its focus on digital transformation in precision monitoring and management systems for chronic diseases such as diabetes, achieving both technological breakthroughs and diversified business expansion.

In 2025, Sinocare completed the R&D of its second-generation continuous glucose monitoring (CGM) system, which has been launched in the domestic market. The product significantly enhances user convenience and wearing comfort and has also obtained EU CE-MDR certification.

Sinocare continued to expand in emerging global markets through an intensive market cultivation model. Overseas revenue reached CNY 997 million in H1 2025, up 7.06% year-on-year, accounting for 44.06% of total revenue. To date, Sinocare’s glucose meters are available in 3,800 tertiary hospitals, over 400,000 pharmacies, and more than 10,000 community and township hospitals, while also being distributed across 20 major e-commerce platforms. Its business footprint spans 187 countries and regions, serving over 25 million users worldwide.

Andon Health Invests in Chromai, a High-End Chromatography Firm

Chromai Technologies Co.,Ltd. (“Chromai”) announced the completion of an A-round of strategic financing, led by Andon Health Co., Ltd. The financing will support Chromai in consolidating its core advantages in mid-to-high-end ultra-high-performance liquid chromatography (UHPLC) systems, accelerating its global competitiveness, and expanding industry-specific and customized solutions for the high-end scientific instrumentation market.

In 2025, Chromai achieved further breakthroughs in UHPLC technology with its upgraded ultra-high-pressure binary pump UP26T (built with titanium alloy biocompatible materials) and quaternary pump UP40, incorporating multiple innovative technologies. It has become the world’s second manufacturer to achieve pressure resistance beyond 20,000 Psi (1380 Bar). With this capital infusion, Chromai aims to deepen its innovation in UHPLC and strengthen the “technological foundation” and “standards framework” for the autonomous development of China’s high-end scientific instrumentation sector.

Rendu Biotechnology Achieves EU IVDR CE Certificates for Three Nucleic Acid Test Kits

On August 29, Rendu Biotechnology announced that three of its nucleic acid testing products have received IVDR CE certification from TÜV SÜD, a European notified body. The certification enables these products to enter the EU market, strengthening the Rendu Biotechnology’s competitiveness in the European in vitro diagnostics sector and expected to positively impact its future business development.